Are you Dr. Jackson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
80 Doctors Dr
Ste 1
Hendersonville, NC 28792Phone+1 828-654-0073Fax+1 828-681-5036
Summary
- Dr. Don Jackson Jr., MD is an oncologist in Hendersonville, North Carolina. He is currently licensed to practice medicine in North Carolina. He is affiliated with AdventHealth Hendersonville, Mission Hospital, and Charles George Veterans Affairs Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1975 - 1977- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1973 - 1975
Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 1972 - 1973
University of Virginia School of MedicineClass of 1972
Certifications & Licensure
NC State Medical License 1978 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- DOSE‐RELATED PHARMACOLOGIC EFFECTS OF HIGH DOSE ARA‐C AND ITS USE IN COMBINATION WITH ASPARAGINASE FOR THE TREATMENT OF PATIENTS WITH ACUTE NON‐LYHPHOCYTIC LEUKEMIA*Robert L. Capizzi, Bayard L. Powell, M. Robert Cooper, James P. Rathmell, J. Courtland White
Scandinavian Journal of Haematology. Supplementum. 2009-04-24 - 252 citationsPhase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089Daniel G. Haller, Paul J. Catalano, John S. Macdonald, Mark Allen O'Rourke, Michael S. Frontiera
Journal of Clinical Oncology. 2005-12-01 - 35 citationsPhase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.William R. Berry, James W. Hathorn, Shaker R. Dakhil, David M. Loesch, Don V. Jackson
Clinical Prostate Cancer. 2004-09-01
Press Mentions
Helping Drug Users Survive, Not Abstain: ‘Harm Reduction’ Gains Federal SupportJune 27th, 2021
Professional Memberships
- Member
